Meat and Poultry in Spain: Liver Failure – Pipeline Review, H1 2012

  • February 2014
  • -
  • Global Markets Direct
  • -
  • 71 pages

This report provides information on the therapeutic development for Liver Failure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Failure. 'Liver Failure - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of the Research

- A snapshot of the global therapeutic scenario for Liver Failure.
- A review of the Liver Failure products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Liver Failure pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Identify and understand important and diverse types of therapeutics under development for Liver Failure.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Liver Failure pipeline depth and focus of Liver Failure therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global March kets Direct Report Coverage 5
Liver Failure Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Liver Failure 7
Liver Failure Therapeutics under Development by Firms 9
Liver Failure Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Liver Failure Therapeutics - Products under Development by Firms 14
Liver Failure Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Liver Failure Therapeutics Development 16
Geron Corporation 16
Angion Biomedica Corp. 17
Liver Failure - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
ANG-1170 - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
ANG-2864 - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
N-Acetylcysteine - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Allogenic Bone March row Stem Cells Transplant - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
ALF-5755 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Hepatocytes - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Liver Failure Therapeutics - Dormant Products 29
Liver Failure - Product Development Milestones 30
Featured News and Press Releases 30
September 21, 2011: Digna Biotech Receives FDA Orphan Drug Status For Cardiotrophin-1 For Acute Liver Failure Treatment 30
May 05, 2011: Alfact Innovation Receives Orphan Drug Designation For ALF-5755 From FDA 30
March 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I 31
March 10, 2011: Digna Biotech And Biotecnol Announce Spanish Approval For Phase I Clinical study Of Cardiotrophin I 31
May 15, 2009: Cardiotrophin-1 Showed To Improve Ssurvival In A Rabbit Model Of Fulminant Hepatic Failure (FHF) Of Viral Origin 32
May 06, 2008: University of Edinburgh Human Embryonic Stem Cell Program Awarded UK Grant Funding 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 35
Contact Us 35
Disclaimer 35

List of Tables

Number of Products Under Development for Liver Failure, H1 2012 7
Products under Development for Liver Failure - Comparative Analysis, H1 2012 8
Number of Products under Development by Firms, H1 2012 9
Number of Products under Investigation by Universities/Institutes, H1 2012 10
Comparative Analysis by Late Stage Development, H1 2012 11
Comparative Analysis by Mid Clinical Stage Development, H1 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 13
Products under Development by Firms, H1 2012 14
Products under Investigation by Universities/Institutes, H1 2012 15
Geron Corporation, H1 2012 16
Angion Biomedica Corp., H1 2012 17
Assessment by Monotherapy Products, H1 2012 18
Assessment by Stage and Route of Administration, H1 2012 20
Assessment by Molecule Type, H1 2012 22
Liver Failure Therapeutics - Dormant Products 29

List of Figures

Number of Products under Development for Liver Failure, H1 2012 7
Products under Development for Liver Failure - Comparative Analysis, H1 2012 8
Products under Development by Firms, H1 2012 9
Products under Investigation by Universities/Institutes, H1 2012 10
Late Stage Products, H1 2012 11
Mid Clinical Stage Products, H1 2012 12
Discovery and Pre-Clinical Stage Products, H1 2012 13
Assessment by Monotherapy Products, H1 2012 18
Assessment by Route of Administration, H1 2012 19
Assessment by Stage and Route of Administration, H1 2012 20
Assessment by Molecule Type, H1 2012 21
Assessment by Stage and Molecule Type, H1 2012 22

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Enabling Technological Platforms for Lab-on-Chip Applications  (Technical Insights)

Enabling Technological Platforms for Lab-on-Chip Applications (Technical Insights)

  • $ 6 500
  • Industry report
  • June 2014
  • by Frost & Sullivan

6 Dimensional Assessment of Lab on a Chip Innovation Landscape A growing trend towards miniaturizing laboratory practices has been a major driving force behind the steady increase of innovations in the ...

Global Proteomics Market

Global Proteomics Market

  • $ 4 950
  • Industry report
  • May 2014
  • by Global Industry Analysts

This report analyzes the worldwide markets for Proteomics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of ...

Label-Free Detection Market by Technology (Bio-layer interferometry, Optical waveguide grating technology, Surface Plasmon resonance), Consumables & Instruments, Applications (Lead Generation, Binding Kinetics), End user - Global Forecasts & Trends to 201

Label-Free Detection Market by Technology (Bio-layer interferometry, Optical waveguide grating technology, Surface Plasmon resonance), Consumables & Instruments, Applications (Lead Generation, Binding Kinetics), End user - Global Forecasts & Trends to 201

  • $ 4 650
  • Industry report
  • April 2014
  • by MarketsandMarkets

Label-free technology is rapidly gaining widespread acceptance as a drug discovery and life science research tool. Currently, the drug discovery process is based on target identification and screening ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.